Hengrui pharmaceutical's revenue in 2018 was 17.418 billion yuan, with a year-on-year increase of over 50% in R & D

[China Pharmaceutical network enterprise news] on February 16, Hengrui pharmaceutical announced its 2018 annual report Data shows that in 2018, the company realized revenue of 17.418 billion yuan, a year-on-year increase of 25.89%; net profit attributable to shareholders of listed companies was 4.066 billion yuan, a year-on-year increase of 26.39%; net profit attributable to shareholders of the company, excluding non recurring profit and loss, was 3.803 billion yuan, a year-on-year increase of 22.60% Specifically, in 2018, Hengrui's anti-tumor business revenue was 7.395 billion yuan, an increase of 29.23% over the same period of last year; anesthesia business revenue was 4.653 billion yuan, an increase of 29.25% over the same period of last year; contrast agent business revenue was 2.324 billion yuan, an increase of 22.67% over the same period of 2017; other business revenue was 3.030 billion yuan, an increase of 16.21% over the same period of last year For performance growth, Hengrui pharmaceutical said that it was mainly driven by two factors, namely, the harvest of innovation achievements and the optimization of the company's product structure On the one hand, the gradual harvest of innovation results has played a driving role in the growth of the company's performance On the other hand, with the adjustment of the company's product structure, the company's non anti-tumor drug products, represented by surgical anesthesia, contrast agents and characteristic infusion, have gradually expanded their markets in their respective treatment fields, and continue to maintain a stable growth trend In terms of innovation achievements, at present, Hengrui pharmaceutical has successively approved the listing of four innovative drugs, including iricoxib, apatinib, thiopefigeristine injection and pyrrolidine It should be mentioned that the continuous approval of the company's innovative products benefits from the increasing R & D investment to a large extent According to the company's financial statements in the past three years, the proportion of its R & D investment and revenue in the same year increased rapidly from 10.68% in 2016 to 15.33% in 2018 In 2018, Hengrui pharmaceutical invested a total of 2.67 billion yuan in R & D, a year-on-year increase of 51.81%, another level higher than the growth rate of 48.53% in 2017 According to the public information, as the leading domestic medicine company, the company's main business involves drug research and development, production and sales, and its main products cover many fields such as anti-tumor drugs, surgical anesthesia drugs, special infusion, contrast agents, cardiovascular drugs, etc In the future, Hengrui pharmaceutical said that it will continue to steadily promote R & D innovation and internationalization of pharmaceutical products, meanwhile, it will also focus on the optimization and improvement of product structure to ensure the sustainable growth of the company's performance.